Introduction. The prognosis of dermatomyositis (DM)/ polymyositis (PM) in adults is partly related to their association with neoplasia. The aim of our study was to report the epidemiologic, clinical, paraclinical, therapeutic and evolutionary aspects of DM associated with malignancy in patients from Sfax, south eastern of Tunisia.
INTRODUCTION
Dermatomyositis (DM) and polymyositis (PM) are autoimmune disorders characterized by inflammatory myopathy belonging to the group of connective tissue disorders. They are often idiopathic but may sometimes be associated with neoplasia. The association between DM and cancer has been reported since 1916 by Stertz [1] . Several studies since then had reported a 3-to 6-fold increase in the risk of malignancy in patients with DM [2] . The association between cancer and myositis is widely variable in literature series. The present study aimed to evaluate the prevalence of malignancy in patients with DM/PM in Sfax (South-Eastern of Tunisia). We also studied the characteristics of the major type of the associated cancer, patient's age and gender and its prognosis. We emphasize on risk factors that must alert clinicians to search for underlying cancer, referring to our literature findings.
MATERIAL AND METHODS
We conducted a descriptive and retrospective study of all cases of paraneoplastic DM/PM followed at the Dermatology and Internal Medicine Departments of Hedi Chaker University Hospital (a tertiary care center) between 1996 and 2015. Diagnosis was based on Bohan and Peter criteria. We collected epidemiological, clinical, paraclinical, therapeutic and outcome data from registered medical observations.
RESULTS
During 20 years, 126 cases of DM/PM were diagnosed. Seventeen were paraneoplastic (13.5%) distributed into 14 cases of DM and 3 cases of PM. For the whole group, at presentation, the mean age of patients was 56.5 years (range 34-83yr) and the sex ratio M/F was 0.3. Symptoms evolved for a mean period of 3.6 months (range: 1-23 months).
In DM patients, mean age was 57.2 years (range: 34-83 years) and the sex-ratio M/F was 0.28. The main clinical manifestations were: impaired general condition (4 cases, 28.5%), erythroedema of the face particularly the orbital rim (11 cases, 78%), periungual erythema (5 cases, 36%), Gottron's papules (1 case, 7%), and myalgia with proximal muscle weakness (12 cases: 85.7%). Skin necrosis was noted in only one patient and pruritus was present in 2 cases. Biological tests noted acceleration of erythrocyte sedimentation rate (ESR) (13 cases, 93%) and elevated muscle enzymes (11 cases, 78%). Elevated creatine phosphokinase (CPK) was constant except in 3 cases. Electromyography (EMG) findings were consistent with myositis in 64.2% of cases. Muscle biopsy performed in 5 patients confirmed the diagnosis in 4 cases. Two patients had amyopathic DM (11.7%). The majority of patients (9 cases; 64.2%) had been already diagnosed with neoplasia and the median time elapsed between discovery of cancer and diagnosis of DM was 2.8 years (range, 6 months -12 years). Etiological investigations disclosed a latent malignancy in 35.7% of cases, mostly following the first year (8 cases, 57.2%) or at the same time of diagnosis of DM (3 cases, 21.5%). Associated cancers were: breast cancer (6 cases, 42.8%), nasopharynx carcinoma (2 cases, 14.2%), colon carcinoma (2 cases, 14.2%), urinary tract carcinoma(2 cases, 14.2%), ovary carcinoma (1 case, 7%) and malignant thymomas (1 case, 7%). After transient recovery of 10.6 months (range 2-24 months), DM recurred in 3 patients, announcing metastases (Table1).
In PM patients, only one patient had breast cancer diagnosed two years before PM. The diagnosis of malignancy followed the one of PM in two cases after a median time of 2 months (range, 1-3 months). Impairment of general condition and myalgia, with accelerated ESR and myolysis were constant. The diagnosis of PM was confirmed by EMG and muscle biopsy in the 3 patients. Associated cancers were breast carcinoma, gallbladder carcinoma and lymphoma (Table 2 ).
All patients were treated with corticosteroids at high doses and with methotrexate in 4 cases. A relapse was observed after initial improvement, in 3 cases of DM, and disclosed metastasis. Outcome was fatal in 5 cases (29.4%), due to the underlying cancer in 3 cases. Swallowing disorders related to DM/PM were responsible for death in 2 cases (Tables 1, 2) .
DISCUSSION
DM and PM are rare inflammatory myopathies [3] . Their prognosis in adults is mainly determined by their association with neoplasia [4, 5] . The association of DM with cancer is well established since 1916 [1, 3] , whereas the relationship between PM and cancer is weaker [6] but it is becoming more common [5, 7] . Paraneoplastic DM's frequency is variously estimated through different series [4, 8] . The incidence varies from 15 to 54% [4, [7] [8] [9] [10] . In Tunisia, according to a multicenter retrospective study, it is estimated at 15% [10] . The incidence of cancer in DM is 5 to 7 times greater than that of the general population [7] . As in our study, the reported mean age of association myositis and cancer is 59.5 years [3] with a female predominance [10] . The risk of this association is higher among men over 50 years [7, 8, 11] . In children, this association has not been described yet. Paraneoplastic DM/PM has no specific clinical or paraclinical features [5] . In DM, cutaneous signs are always present and muscle symptoms appear simultaneously or later after skin involvement [5] . The neck and the back of the hands are electively involved [5] . Erythema is classic, appearing on outset or during the evolution of atrophy beaches. Zarrabi et al. reported a rare case of edematous paraneoplastic DM with florid subcutaneous edema [12] . In prolonged cases, poïkilo-DM can appear. DM associated with cancer is amyopathic in 22% of cases [4, 13, 14] , this association was noted in 11.7% of cases in our study. Some cases reported mucinosis as the only manifestation of DM [15, 16] . Skin necrosis, observed only in one patient of our series, was reported in 62% of DM associated with cancer and in 7% of non-paraneoplastic DM [9] . High levels of muscle enzymes are common [9] . Elevated ESR, noted in 93% of our cases, was also noted in DM associated with cancer [5] .
Poor prognostic factors in DM that must alert for the possibility of associated neoplasia are: older age (more than 50 years at diagnosis [3, 8, 17, 18] ), rapid onset, extensive skin lesions [19] , pruritus [4] , necrosis [6] and increased ESR [20] . Several studies have also found that the presence of certain antibodies in myositis such as anti JO1, anti Mi2 and anti U1RNP is associated with a low risk of cancers [21] . Nevertheless, the anti-155/140 antibodies are associated with a higher risk of cancer in DM [22] . It was recently established that anti-SAE1, and previously reported anti-TIF1-γ and anti-NXP2 antibodies, are all associated with an increased risk of cancer in patients with DM/PM. It could be a tool for etiologic research of paraneoplastic DM/ PM [23] . Unfortunately, these laboratory tests were not performed in our study because of the lack of suitable kit. Oesophagus (1); stomach (3); colon (7); lung (19); breast (3); cervix uteri (2); ovary (2); prostate (1); bladder (1); unspecified (6); Hodgkin's disease (1); Non-Hodgkin's lymphoma (2) Chen et al. lung cancers (7), prostate cancers (6), colon cancers (4), lymphomas (4), Hodgkin's disease (2), leukaemias (3), breast (3), melanomas(2), skin cancers (3), bladder ( 3) endometrial ( 1) testis (1), unspecified, site (1), 1nasopharyngeal( 1), pancreatic (1) and myelodysplastic syndrome (1) Requena et al. Breast carcinoma (7), Gallbladder carcinoma (1), Lymphoma (1), Thymoma (1), Urinary tract carcinoma (2), Colon carcinoma (2), Nasopharynx carcinoma (2), Ovary carcinoma (1) DM/PM could follow an already diagnosed cancer, as 10 of our patients, but it often precedes cancer by several months [17, 18] . The risk of cancer occurrence seems to be greater in the first year of DM/PM diagnosis [3, 6, 11, 24] . Associated cancers do not seem to differ from those frequent in general population [10] . In general, carcinomas are more frequent than sarcomas and lymphoproliferative tumors. These cancers are dominated by breast cancer in women (41% in our series) [7, 9, 25] and lung cancers in men [7, 9] . According to Hendren et al., the presence of DM is associated with moreadvanced breast cancer stage and is most commonly associated with invasive ductal carcinoma [26] . Other cancers were reported especially colorectal cancers, cancers of the ovary [3] , the nasophagynx, the prostate [27, 28] . But, all localizations are possible: kidney, thyroid, malignant thymoma or lymphoma. Cancers of unknown primary-related DM had also been reported [29] . Zhang et al. reported a rare case of occult breast cancer in a man associated to DM [30] . To date and to our knowledge related to skin cancers, yet so common, had not been reported (Table 3 : DM/PM and type of associated malignancy in different populations).
There is often a clear correlation between changes in DM and those of the associated cancer [27] . For some patients, cancer treatment results in DM improvement or even recovery from DM [33] . If metastases appear, DM may recur. The latter situation was noted in 3 of our patients. DM was reported in association to a recurrence of breast cancer [25] .
Disclosure of a cancer in a patient with DM is a poor prognostic factor. Mortality ranges from 35 to 58% after 20 months and 7 years, respectively [10] . It reaches 100% in case of severe forms of DM [4] . DM may be fatal, by swallowing disorders associated with muscle impairment as in 2 of our patients, but death is linked to cancer in 90% of cases [10] .
Etiopathogenesis of this paraneoplastic syndrome remains controversial [6, 7] . Some authors propose an alteration of the extracellular matrix of the skin by increased inflammatory and immunological reaction in patient's skin. DM and some cancers share etiologic factors [6] .
As the pathophysiology of paraneoplastic DM/PM remains unclear, no standard treatment regimen has been established yet [34] . High-dose corticosteroids are suggested as the first-line therapy. It was the therapeutic choice for all our patients. Immunosuppressant drugs or IV human immunoglobulins are suggested as second-line therapy. Drugs administered in case of DM do not seem to increase the risk of cancers [6] . Searching for neoplasia in DM is discussed [3] , this assessment is systematic in adults for some authors [9] , mainly if they had a history of neoplasia, rapid onset of DM, recurrence or sudden worsening of previously stable DM [24] . Some authors recommended repeated investigations at regular intervals of 6 to 12 months after diagnosis to prevent discovery of cancer at advanced stage [35] . Gkegkes et al. had even suggested to perform systematic colonoscopy in these patients [36] .
CONCLUSION
In adult patients with DM/ PM, the presence of predictive factors such as advanced age, impairment of general condition and accelerated ESR must alert clinicians to the possibility of associated neoplasia. Thorough physical examination and accurate investigations are needed to detect cancer at an early stage. In our series, breast neoplasm represents the first cancer associated with DM. Cancers of nasopharynx, colon and urinary tract have the second position. Our study confirms correlation between neoplasia and DM's outcomes. The limitations of our study are the small number of patients with cancer and it would have been interesting to make comparisons with DM/PM patients that had no neoplasias and search for some distinct characteristics. 
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